Skip to main content
. 2017 Apr 1;7(4):831–844.

Figure 5.

Figure 5

Trametinib treatment led to decreased VEGFA levels and NRAS signaling in vivo. A. VEGFA and CD31 levels from tumor samples were analyzed through Western blot analysis. Lower CD31 and VEGFA levels were measured in the trametinib treatment group. B. Similarly, through Western blot, trametinib treatment had the most profound decrease in CRAF, BRAF and NRAS protein levels in tumor samples.